ArticleFrontiers in immunology2022

Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses.

Giulia Monticone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.